Page last updated: 2024-12-07

moexipril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Moexipril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure. It works by blocking the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor. This results in vasodilation and reduced blood pressure. Moexipril was synthesized by researchers at Merck & Co. in the 1970s. It is well-absorbed orally and has a long half-life. Moexipril has been shown to be effective in reducing blood pressure and improving cardiovascular outcomes in patients with hypertension. It is also used to treat heart failure and diabetic nephropathy. Moexipril is a popular medication for managing hypertension, and its synthesis, effects, and importance in treating cardiovascular diseases are actively studied. '

Cross-References

ID SourceID
PubMed CID91270
CHEMBL ID1165
CHEBI ID6960
SCHEMBL ID34030
MeSH IDM0162643

Synonyms (46)

Synonym
BIDD:GT0007
BRD-K34441861-003-01-3
AKOS015843317
(3s)-2-(n-{(1s)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-l-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
uniretic
moexipril
103775-10-6
C07704
DB00691
moexipril [inn:ban]
(3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester
moexiprilum [inn-latin]
(s)-2-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
bdbm50084673
1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-indole-2-carboxylic acid(moexipril)
chebi:6960 ,
CHEMBL1165 ,
moexipril (inn)
D08225
(3s)-2-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid
A800803
109715-88-0
unii-wt87c52tjz
wt87c52tjz ,
moexiprilum
moexipril [mi]
moexipril [vandf]
(3s)-2-((2s)-2-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
moexipril [inn]
3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, (3s-(2(r*(r*)),3r*))-
moexipril [who-dd]
gtpl6571
SCHEMBL34030
UWWDHYUMIORJTA-HSQYWUDLSA-N
AB01565830_02
DTXSID9023330
(3s)-2-[(2s)-2-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Q2291605
3-isoquinolinecarboxylic acid,2-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, (3s)-
4-(4-oxopiperidine-1-carbonyl)phenylboronicacid
(s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
NCGC00263546-03
(s)-2-((s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
EN300-19766737
HY-117281
CS-0064930

Research Excerpts

Overview

Moexipril is an ACE inhibitor with a lipophilicity in the same range as quinapril, benazepril or ramipril. It needs to be hydrolyzed in the liver into its active carboxylic metabolite, moxiprilat, to become effective.

ExcerptReferenceRelevance
"Moexipril is an ACE inhibitor with a lipophilicity in the same range as quinapril, benazepril or ramipril, and so can readily penetrate lipid membranes and thus target tissue ACE in addition to plasma ACE."( ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
Fisman, EZ; Pines, A, 2003
)
1.36
"Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective."( Pharmacological and clinical profile of moexipril: a concise review.
Chrysant, GS; Chrysant, SG, 2004
)
1.31
"Moexipril is an ACE inhibitor which in women demonstrated its doubtless antihypertensive efficacy with additional favorable properties."( [Moexipril and cardiovascular diseases in women: is there a reason for optimism?].
, 2006
)
1.97
"Moexipril is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor. "( Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS.
Gulyás, Z; Kalász, H; Klebovich, I; Ludányi, K; Petroianu, G; Tekes, K, 2007
)
2.14
"Moexipril hydrochloride is a long-acting, non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension."( Moexipril and left ventricular hypertrophy.
Chrysant, GS; Nguyen, PK, 2007
)
2.5
"Moexipril is a new nonpeptide angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action. "( Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.
Fox, A; Persson, B; Stimpel, M; Widgren, BR, 1995
)
2.03
"Moexipril is a new, long-acting angiotensin-converting enzyme (ACE) inhibitor. "( Moexipril versus captopril in patients with mild to moderate hypertension.
Fox, A; Jansen, T; Koch, B; Loh, I; Stimpel, M, 1996
)
3.18
"Moexipril is a prodrug which is hydrolysed after oral administration to its active metabolite moexiprilat, an inhibitor of the angiotensin converting enzyme (ACE). "( Moexipril. A review of its use in the management of essential hypertension.
Brogden, RN; Wiseman, LR, 1998
)
3.19

Effects

Moexipril has a hypotensive and nephroprotective effects, improves endothelial function and quality of life in hypertensive postmenopausal women. It has now also been demonstrated to have beneficial effects on LVH.

ExcerptReferenceRelevance
"Moexipril has a hypotensive and nephroprotective effects, improves endothelial function and quality of life in hypertensive postmenopausal women."( [Moexipril influence on quality of life in postmenopausal women with arterial hypertension].
Belousov, IuB; Demidova, MA; Glezer, MG; Tkhostova, EB, 2005
)
2.68
"Moexipril has a hypotensive and nephroprotective effects, improves endothelial function and quality of life in hypertensive postmenopausal women."( [Moexipril influence on quality of life in postmenopausal women with arterial hypertension].
Belousov, IuB; Demidova, MA; Glezer, MG; Tkhostova, EB, 2005
)
2.68
"Moexipril has now also been demonstrated to have beneficial effects on LVH and can lead to LVH regression."( Moexipril and left ventricular hypertrophy.
Chrysant, GS; Nguyen, PK, 2007
)
2.5

Treatment

Moexipril treatment lowered urinary protein excretion to a normal range and completely prevented glomerular injury. Treatment with moexipil or enalapril dose-dependently reduced the percentage of damaged neurons.

ExcerptReferenceRelevance
"Moexipril treatment lowered urinary protein excretion to a normal range and completely prevented glomerular injury."( Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started.
Amuchastegui, SC; Bertani, T; Colosio, V; Perico, N; Remuzzi, G; Sonzogni, G, 1994
)
1.01
"Treatment with moexipril was associated with two cases of first dose hypotension and two cases of moderate and reversible increases in serum creatinine levels."( Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.
Persson, B; Stimpel, M, 1996
)
0.87
"Treatment with moexipril or enalapril dose-dependently reduced the percentage of damaged neurons, as well as mitochondrial reactive oxygen species generation induced by glutamate, staurosporine or Fe2+/3+."( Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats.
Ahlemeyer, B; Culmsee, C; Junker, V; Kouklei, M; Krieglstein, J; Ravati, A, 1999
)
1

Toxicity

Blood pressure, pulse rate, weight, adverse side-effects and laboratory studies were assessed following moexipril dosing at 7.

ExcerptReferenceRelevance
"5) represents a safe drug without relevant side effects or gross toxicity."( Preclinical safety studies of the combination moexipril hydrochloride/hydrochlorothiazide.
Friehe, H; Gietl, R; Ney, P, 1998
)
0.56
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

Moexipril is a new converting enzyme inhibitor. Co-administration with hydrochlorothiazide had no demonstrable effect on the measured pharmacokinetic parameters.

ExcerptReferenceRelevance
" Apparent volume of distribution, peak plasma concentration, time to reach peak concentration and area under the plasma concentration-time curve both of (R)- and (S)-warfarin were not significantly affected."( Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.
Angehrn, J; Cawello, W; De Schepper, PJ; Depré, M; Tjandramaga, TB; Van Hecken, A; Verbesselt, R, 1993
)
1.73
"To investigate the potential for pharmacokinetic interactions between moexipril, a new converting enzyme inhibitor, and hydrochlorothiazide after single dose administration."( Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.
Angehrn, JC; Bonn, R; Cawello, W; De Schepper, PJ; Hutt, V; Michaelis, K; Salomon, P; Verbesselt, R, 1996
)
0.79
" The Cmax of moexipril and the metabolite (data of the metabolite in parenthesis) were 245."( Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.
Angehrn, JC; Bonn, R; Cawello, W; De Schepper, PJ; Hutt, V; Michaelis, K; Salomon, P; Verbesselt, R, 1996
)
0.92
"The coadministration of moexipril with hydrochlorothiazide had no demonstrable effect on the measured pharmacokinetic parameters of moexipril, its active metabolite moexiprilat or hydrochlorothiazide."( Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.
Angehrn, JC; Bonn, R; Cawello, W; De Schepper, PJ; Hutt, V; Michaelis, K; Salomon, P; Verbesselt, R, 1996
)
0.86
"Moexiprilat showed an extended duration of action owing to a long terminal pharmacokinetic half-life and produced a persistent ACE inhibition."( Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Boekens, H; Cawello, W; Miller, U; Waitzinger, J, 2002
)
3.2

Compound-Compound Interactions

ExcerptReferenceRelevance
"The purpose of this study was to evaluate the long-term safety and efficacy of moexipril, a non-sulphydryl angiotensin converting enzyme inhibitor, alone or in combination with hydrochlorothiazide in older patients with hypertension."( Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.
Stimpel, M; White, WB, 1995
)
0.8

Bioavailability

ExcerptReferenceRelevance
" Possible mechanisms include poor drug permeability, a pH effect whereby the zwitterionic form of the drug is more rapidly absorbed, and esterase cleavage of moexipril to the poorly absorbed moexipril diacid."( Evidence for site-specific absorption of a novel ACE inhibitor.
Grass, GM; Morehead, WT, 1989
)
0.47
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34

Dosage Studied

Three simple, accurate, reproducible, and selective methods have been developed and subsequently validated for the simultaneous determination of Moexipril (MOX) and Hydrochlorothiazide (HCTZ) in pharmaceutical dosage form.

ExcerptRelevanceReference
" However, pharmacokinetic studies with the controlled-release dosage forms in humans produced plasma profiles with the same characteristics and time to peak as an immediate-release capsule."( Evidence for site-specific absorption of a novel ACE inhibitor.
Grass, GM; Morehead, WT, 1989
)
0.28
" Similarly, after long-term dosing for 8 weeks, reductions in 24-hour diastolic BPs were 1/-2 mm Hg, -6/-4 mm Hg, and -12/-9 mm Hg for the respective treatment groups (P < ."( Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring.
Fox, AA; Kaihlanen, PM; Stimpel, M; Whelton, A; White, WB, 1995
)
0.53
" The only activity observed in mice was an inhibition of spontaneous motility after oral dosing with 300 and 1000 mg/kg, respectively."( Preclinical safety studies of the combination moexipril hydrochloride/hydrochlorothiazide.
Friehe, H; Gietl, R; Ney, P, 1998
)
0.56
" The primary efficacy variable was the mean change from baseline in seated diastolic BP at the end of the dosing period."( Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension.
Koch, B; Stimpel, M; White, WB, 1997
)
0.66
" In the third study, the pharmacokinetics after multiple dosing of 15 mg moexipril once daily for 5 days were investigated in 12 young and 12 elderly subjects."( Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Boekens, H; Cawello, W; Miller, U; Waitzinger, J, 2002
)
1.99
" With repeated dosing there were no signs of drug accumulation and day-to-day drug levels were relatively constant."( Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Boekens, H; Cawello, W; Miller, U; Waitzinger, J, 2002
)
1.76
"Three simple, accurate, reproducible, and selective methods have been developed and subsequently validated for the simultaneous determination of Moexipril (MOX) and Hydrochlorothiazide (HCTZ) in pharmaceutical dosage form."( Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for simultaneous quantitation of Moexipril and Hydrochlorothiazide.
Elaziz, OA; Farouk, M; Hemdan, A; Shehata, MA; Tawakkol, SM, 2014
)
0.81
" The method was applied to the assay of BNZ in combined dosage form with no interference from other ingredients."( Kinetic Profiling of the Hydrolytic Reaction of Benazepril: Metabolic Pathway Simulation.
Hemdan, A; Michael, AM, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.04270.00010.533610.0000AID39758; AID39767
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)0.05600.00042.207910.0000AID39758
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (78)

Processvia Protein(s)Taxonomy
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID39758Inhibition of guinea pig angiotensin I converting enzyme1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID186544Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 10 mg/kg administered orally at 6 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID186362Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 1 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID186360Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 10 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID186674Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 1 mg/kg administered orally at 6 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID186538Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 0.3 mg/kg administered orally at 5 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID186366Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 3 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID186687Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 3 mg/kg administered orally at 6 hr.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID39767Inhibitory activity against angiotensin I converting enzyme (ACE)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID186359Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 0.3 mg/kg administered orally.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (9.57)18.7374
1990's35 (37.23)18.2507
2000's31 (32.98)29.6817
2010's15 (15.96)24.3611
2020's4 (4.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.06 (24.57)
Research Supply Index4.86 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index78.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (29.29%)5.53%
Reviews10 (10.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (60.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Relative Bioavailability Study of Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions [NCT00835042]Phase 160 participants (Actual)Interventional2003-10-31Completed
A Relative Bioavailability Study of Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions [NCT00834067]Phase 160 participants (Actual)Interventional2003-10-31Completed
A Relative Bioavailability Study of Moexipril HCl 15mg Tablets Under Fasting Conditions [NCT00992862]Phase 160 participants InterventionalCompleted
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide 15mg/25mg Tablets (Paddock Laboratories, Inc) and Uniretic® 15mg/25mg Tablets (Schwarz Pharma)(Moexipril HCl/Hydrochlorothiazide) in Healthy Adult Volunteers Under Fastin [NCT00990301]Phase 148 participants (Actual)InterventionalCompleted
Open-Label Pilot Investigation of Moexipril for the Treatment of Primary Biliary Cirrhosis (PBC) [NCT00588302]Phase 220 participants (Actual)Interventional2003-06-30Completed
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study [NCT01669434]Phase 4291 participants (Actual)Interventional2015-06-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00834067 (9) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.
NCT00834067 (9) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.
NCT00834067 (9) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.
NCT00834067 (9) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.
NCT00834067 (9) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.
NCT00834067 (9) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.
NCT00834067 (9) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.
NCT00834067 (9) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.
NCT00834067 (9) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.
NCT00835042 (9) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.
NCT00835042 (9) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.
NCT00835042 (9) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.
NCT00835042 (9) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.
NCT00835042 (9) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.
NCT00835042 (9) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.
NCT00835042 (9) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.
NCT00835042 (9) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.
NCT00835042 (9) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.
NCT01669434 (6) [back to overview]Acute Renal Failure
NCT01669434 (6) [back to overview]Low Blood Pressure Subgroup
NCT01669434 (6) [back to overview]Number of Participants With Interoperative Hypotension
NCT01669434 (6) [back to overview]Older Age Subgroup
NCT01669434 (6) [back to overview]Postoperative Hypertension
NCT01669434 (6) [back to overview]Postoperative Hypotension

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.

Bioequivalence based on AUC0-inf. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)1115.905
Reference (Uniretic®)1108.329

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.

Bioequivalence based on AUC0-inf. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)36.651
Reference (Uniretic®)35.74

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.

Informational comparison of AUC0-inf values for the metabolite Moexiprilat. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)376.814
Reference (Uniretic®)379.994

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.

Bioequivalence based on AUC0-t. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)1105.63
Reference (Uniretic®)1100.5

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.

Bioequivalence based on AUC0-t. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)35.412
Reference (Uniretic®)34.917

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.

Informational comparison of AUC0-t values for the metabolite Moexiprilat. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)215.654
Reference (Uniretic®)214.286

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.

Bioequivalence based on Cmax. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng/mL (Mean)
Test (Moexipril HCl/HCTZ)150.225
Reference (Uniretic®)148.39

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.

Bioequivalence based on Cmax. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng/mL (Mean)
Test (Moexipril HCl/HCTZ)14.487
Reference (Uniretic®)14.885

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.

Informational comparison of Cmax values for the metabolite Moexiprilat. (NCT00834067)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng/mL (Mean)
Test (Moexipril HCl/HCTZ)5.512
Reference (Uniretic®)5.13

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.

Bioequivalence based on AUC0-inf. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)1001.133
Reference (Uniretic®)1001.548

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.

Bioequivalence based on AUC0-inf. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)55.837
Reference (Uniretic®)54.593

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.

Informational comparison of AUC0-inf values for the metabolite Moexiprilat. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)443.448
Reference (Uniretic®)427.212

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.

Bioequivalence based on AUC0-t. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)992.17
Reference (Uniretic®)994.093

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.

Bioequivalence based on AUC0-t. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)54.517
Reference (Uniretic®)53.598

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.

Informational comparison of AUC0-t values for the metabolite Moexiprilat. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng*h/mL (Mean)
Test (Moexipril HCl/HCTZ)262.231
Reference (Uniretic®)264.991

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.

Bioequivalence based on Cmax. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng/mL (Mean)
Test (Moexipril HCl/HCTZ)153.602
Reference (Uniretic®)145.088

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.

Bioequivalence based on Cmax. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng/mL (Mean)
Test (Moexipril HCl/HCTZ)31.913
Reference (Uniretic®)34.4

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.

Informational comparison of Cmax values for the metabolite Moexiprilat. (NCT00835042)
Timeframe: Blood samples collected over a 192 hour period.

Interventionng/mL (Mean)
Test (Moexipril HCl/HCTZ)20.049
Reference (Uniretic®)21.882

[back to top]

Acute Renal Failure

Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level (NCT01669434)
Timeframe: Arrival in post-anesthesia care unit (PACU) to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission6
ACEI Continuation10

[back to top]

Low Blood Pressure Subgroup

Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg. (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission4
ACEI Continuation2

[back to top]

Number of Participants With Interoperative Hypotension

Number of Participants with Interoperative Hypotension (systolic blood pressure under 80 mmHg) (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission76
ACEI Continuation95

[back to top]

Older Age Subgroup

Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission48
ACEI Continuation49

[back to top]

Postoperative Hypertension

Any systolic blood pressure greater than 180 mmHg. (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission33
ACEI Continuation17

[back to top]

Postoperative Hypotension

Any systolic blood pressure less than 90 mmHg (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission15
ACEI Continuation31

[back to top]